Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation.
Critically ill patients after extended surgical procedures are at high risk for postoperative infections. Fungal infections play a substantial role for immunocompromised patients, e.g. after solid organ transplantation or under chronic corticoid therapy. Posaconazole, a new broad-spectrum triazole effective against Aspergillus and Candida species as well as many fungi that are resistant to other antifungals, is well tolerated and can be used as an alternative in salvage therapy. Posaconazole can be administered via gavage so that antifungal therapy can be switched from an expensive intravenously applied antifungal to oral posaconazole at an early stage. Two case reports are presented, which show that posaconazole was efficacious and well tolerated following antifungal therapy with another azole. It was administered without difficulty via gavage to a patient receiving artificial respiration and dialysis.
Störzinger
Dominic
D
Pharmacy Department, University Hospital of Heidelberg, Heidelberg, Germany. dominic.stoerzinger@med.uni-heidelberg.de
Lichtenstern
Christoph
C
Swoboda
Stefanie
S
Weigand
Markus A
MA
Hoppe-Tichy
Torsten
T
D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000517:prevention & control; D002177:Candidiasis / Q000188:drug therapy / Q000517:prevention & control; D003422:Critical Care; D003428:Cross Infection / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole